The plant-based immunomodulator curcumin as a potential candidate for the development of an adjunctive therapy for cerebral malaria

Malaria Journal

Volumn 10, Issue SUPPL. 1, 2011, Pages

  Mimche, Patrice N ^a,b   Taramelli, Donatella ^b   Vivas, Livia ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACTIVATED CARBON; ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE; ATOVAQUONE; CD36 ANTIGEN; CHLOROQUINE; CURCUMIN; DEFEROXAMINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ERYTHROPOIETIN; FASUDIL; HISTONE ACETYLTRANSFERASE; IMMUNOMODULATING AGENT; INTERLEUKIN 1; INTERLEUKIN 6; LIPOSOME; NANOPARTICLE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOLIPID; PIPERINE; PLACEBO; QUININE; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1;

ADJUVANT THERAPY; ANTIINFLAMMATORY ACTIVITY; ANTIMALARIAL ACTIVITY; AYURVEDA; BRAIN MALARIA; CELL ADHESION; CINCHONA; COGNITIVE DEFECT; CURCUMA LONGA; CYTOKINE PRODUCTION; DIET; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; ENDOTHELIUM CELL; GENE DELETION; HUMAN; IC 50; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MALARIA FALCIPARUM; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARASITE CLEARANCE; PARASITEMIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGOCYTOSIS; PLASMODIUM BERGHEI INFECTION; PLASMODIUM CHABAUDI INFECTION; PREGNANT WOMAN; PROTEIN EXPRESSION; REVIEW; RHIZOME; RISK REDUCTION; SCHIZONT; SEPSIS; SURVIVAL; TREATMENT DURATION; TROPHOZOITE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMALARIALS; CURCUMIN; DIETARY SUPPLEMENTS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOLOGIC FACTORS; MALARIA; MALARIA, CEREBRAL; PLANTS;

EID: 79952746854     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-10-S1-S10     Document Type: Review

References (87)

1. WHO world malaria report 2009. WHO, WHO publication Geneva: World Health Organization 2009 78
2. The management of patients with severe malaria. N Day AM Dondorp, Am J Trop Med Hyg 2007 77 Suppl 6 29 35 18165472
3. Artemisinin resistance in Plasmodium falciparum malaria. AM Dondorp F Nosten P Yi D Das AP Phyo J Tarning KM Lwin F Ariey W Hanpithakpong SJ Lee P Ringwald K Silamut M Imwong K Chotivanich P Lim T Herdman SS An S Yeung P Singhasivanon NP Day N Lindegardh D Socheat NJ White, N Engl J Med 2009 361 455 467 10.1056/NEJMoa0808859 19641202
4. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. AM Dondorp CI Fanello ICE Hendriksen E Gomes A Seni KD Chhaganlal K Bojang R Olaosebikan N Anunobi K Maitland E Kivaya T Agbenyega SB Nguah J Evans S Gesase C Kahabuka G Mtove B Nadjm J Deen J Mwanga-Amumpaire M Nansumba C Karema N Umulisa A Uwimana OA Mokuolu OT Adedoyin WB Johnson AK Tshefu MA Onyamboko T Sakulthaew WP Ngum K Silamut K Stepniewska CJ Woodrow D Bethell B Wills M Oneko TE Peto L von Seidlein NP Day NJ White group AQUAMAT, Lancet 2010 376 1647 1657 10.1016/S0140-6736(10)61924-1 21062666
5. Innate immunity to malaria caused by Plasmodium falciparum. TG Smith K Ayi L Serghides CD McAllister KC Kain, Clin Invest Med 2002 25 262 272 12516999 (Pubitemid 36197497)
6. Immunopathogenesis of cerebral malaria. NH Hunt J Golenser T Chan-Ling S Parekh C Rae S Potter IM Medana J Miu HJ Ball, Int J Parasitol 2006 36 569 582 10.1016/j.ijpara.2006.02.016 16678181 (Pubitemid 43674512)
7. Immunological processes in malaria pathogenesis. L Schofield GE Grau, Nat Rev Immunol 2005 5 722 735 10.1038/nri1686 16138104 (Pubitemid 43086173)
8. Conventional and experimental treatment of cerebral malaria. J Golenser J McQuillan L Hee AJ Mitchell NH Hunt, Int J Parasitol 2006 36 583 593 10.1016/j.ijpara.2006.02.009 16603167 (Pubitemid 43674518)
9. Can erythropoietin be used to prevent brain damage in cerebral malaria? C Casals-Pascual R Idro S Picot DJ Roberts CRJC Newton, Trends Parasitol 2009 25 30 36 10.1016/j.pt.2008.10.002 19008152
10. Oral activated charcoal prevents experimental cerebral malaria in mice and in a randomized controlled clinical trial in man did not interfere with the pharmacokinetics of parenteral artesunate. JB de Souza U Okomo ND Alexander N Aziz BMJ Owens H Kaur M Jasseh S Muangnoicharoen PF Sumariwalla DC Warhurst SA Ward DJ Conway L Ulloa KJ Tracey BM Foxwell PM Kaye M Walther, PLoS ONE 2010 5 9867 10.1371/journal.pone.0009867 20419161
11. Cognitive dysfunction is sustained after rescue therapy in experimental cerebral malaria, and is reduced by additive antioxidant therapy. PA Reis CM Comim F Hermani B Silva T Barichello AC Portella FCA Gomes IM Sab VS Frutuoso MF Oliveira PT Bozza FA Bozza F Dal-Pizzol GA Zimmerman J Quevedo HC Castro-Faria-Neto, PLoS Pathog 2010 6 1000963 10.1371/journal.ppat.1000963 20585569
12. Rosiglitazone modulates the innate immune response to Plasmodium falciparum infection and improves outcome in experimental cerebral malaria. L Serghides SN Patel K Ayi Z Lu DC Gowda WC Liles KC Kain, J Infect Dis 2009 199 1536 1545 10.1086/598222 19392627
13. Modulation of cerebral malaria by fasudil and other immune-modifying compounds. JH Waknine-Grinberg JA McQuillan N Hunt H Ginsburg J Golenser, Exp Parasitol 2010 125 141 146 10.1016/j.exppara.2010.01.005 20093114
14. N-acetylcysteine as adjunctive treatment in severe malaria: a randomized, double-blinded placebo-controlled clinical trial. P Charunwatthana M Abul Faiz R Ruangveerayut RJ Maude MR Rahman LJ Roberts 2nd K Moore E Bin Yunus MG Hoque MU Hasan SJ Lee S Pukrittayakamee PN Newton NJ White NP Day AM Dondorp, Crit Care Med 2009 37 516 522 10.1097/CCM.0b013e3181958dfd 19114891
15. Safety of epoietin beta-quinine drug combination in children with cerebral malaria in Mali. S Picot AL Bienvenu S Konate S Sissoko A Barry E Diarra K Bamba A Djimde O Doumbo, Malar J 2009 8 169 10.1186/1475-2875-8-169 19630971
16. Nonopsonic monocyte/macrophage phagocytosis of Plasmodium falciparum-parasitized erythrocytes: a role for CD36 in malarial clearance. ID McGilvray L Serghides A Kapus OD Rotstein KC Kain, Blood 2000 96 3231 3240 11050008
17. Peroxisome proliferator-activated receptor gamma}-retinoid X receptor agonists increase CD36-dependent phagocytosis of Plasmodium falciparum- parasitized erythrocytes and decrease malaria-induced TNF-alpha secretion by monocytes/macrophages. L Serghides KC Kain, J Immunol 2001 166 6742 6748 11359831 (Pubitemid 32467218)
18. Use of peroxisome proliferator-activated receptor agonists as adjunctive treatment for Plasmodium falciparum malaria: A randomized, double-blind, placebo-controlled trial. AK Boggild S Krudsood SN Patel L Serghides N Tangpukdee K Katz P Wilairatana WC Liles S Looareesuwan C Kevin Kain, Clin Infect Dis 2009 49 841 849 10.1086/605431 19673614
19. Genome wide analysis of inbred mouse lines identifies a locus containing ppar- as contributing to enhanced malaria survival. SER Bopp V Ramachandran K Henson A Luzader M Lindstrom M Spooner BM Steffy O Suzuki C Janse AP Waters Y Zhou T Wiltshire EA Winzeler, PLoS ONE 2010 5 10903 10.1371/journal.pone.0010903 20531941
20. Recombinant human erythropoietin prevents the death of mice during cerebral malaria. K Kaiser A Texier J Ferrandiz A Buguet A Meiller C Latour F Peyron R Cespuglio S Picot, J Infect Dis 2006 193 987 995 10.1086/500844 16518761
21. Artesunate-erythropoietin combination for murine cerebral malaria treatment. AL Bienvenu J Ferrandiz K Kaiser C Latour S Picot, Acta Trop 2008 106 104 108 10.1016/j.actatropica.2008.02.001 18359468
22. High levels of erythropoietin are associated with protection against neurological sequelae in African children with cerebral malaria. C Casals-Pascual R Idro N Gicheru S Gwer B Kitsao E Gitau R Mwakesi DJ Roberts CRJC Newton, Proc Natl Acad Sci USA 2008 105 2634 2639 10.1073/pnas.0709715105 18263734 (Pubitemid 351520565)
23. Blood purification in sepsis: an idea whose time has come? JA Kellum R Venkataraman, Crit Care Med 2002 30 1387 1388 10.1097/00003246-200206000-00047 12072702 (Pubitemid 34620992)
24. A nexus of progression of chronic kidney disease: charcoal, tryptophan and profibrotic cytokines. G Schulman, Blood Purif 2006 24 143 148 10.1159/000089451 16361855 (Pubitemid 41820836)
25. Rho kinase inhibition in severe malaria: Thwarting parasite-induced collateral damage to endothelia. Z Taoufiq F Gay J Balvanyos L Ciceron M Tefit P Lechat D Mazier, J Infect Dis 2008 197 1062 1073 10.1086/528988 18419473 (Pubitemid 351590036)
26. Inhibition of Plasmodium falciparum field isolates-mediated endothelial cell apoptosis by Fasudil: Therapeutic implications for severe malaria. ES Zang-Edou U Bisvigou Z Taoufiq F Lékoulou JB Lékana-Douki Y Traoré D Mazier FS Touré-Ndouo, PLoS ONE 2010 5 13221 10.1371/journal.pone.0013221 20949056
27. Plasmodium falciparum-infected erythrocyte adhesion induces caspase activation and apoptosis in human endothelial cells. P Pino I Vouldoukis P Jean Kolb N Mahmoudi I Desportes-Livage F Bricaire M Danis B Dugas D Mazier, J Infect Dis 2003 187 1283 1290 10.1086/373992 12696008 (Pubitemid 36438969)
28. Transient supplementation of superoxide dismutase protects endothelial cells against Plasmodium falciparum-induced oxidative stress. Z Taoufiq P Pino N Dugas M Conti M Tefit D Mazier I Vouldoukis, Mol Biochem Parasitol 2006 150 166 173 10.1016/j.molbiopara.2006.07.008 16930739 (Pubitemid 44691941)
29. Adjuvant therapy in cerebral malaria. S Mohanty D P SS Pati SK Mishra, Indian J Med Res 2006 124 245 260 17085828 (Pubitemid 44734281)
30. Adhesion of Plasmodium falciparum-infected erythrocytes to human cells: molecular mechanisms and therapeutic implications. JA Rowe A Claessens RA Corrigan Mn Arman, Expert Reviews in Molecular Medicine 2009 11 16 10.1017/S1462399409001082 19467172
31. Embryotoxicity of the artemisinin antimalarials and potential consequences for use in women in the first trimester. RL Clark, Reproductive Toxicology 2009 28 285 296 10.1016/j.reprotox.2009.05.002 19447170
32. Anti-malarial activities of Andrographis paniculata and Hedyotis corymbosa extracts and their combination with curcumin. K Mishra AP Dash BK Swain N Dey, Malar J 2009 8 26 10.1186/1475-2875-8-26 19216765
33. Curcumin and the cellular stress response in free radical-related diseases. V Calabrese TE Bates C Mancuso C Cornelius B Ventimiglia MT Cambria LD Renzo AD Lorenzo AT Dinkova-Kostova, Mol Nutr Food Res 2008 52 1062 1073 10.1002/mnfr.200700316 18792015
34. Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. J Epstein IR Sanderson TT MacDonald, Br J Nutr 2010 103 1545 1557 10.1017/S0007114509993667 20100380
35. Curcumin as "Curecumin": From kitchen to clinic. A Goel AB Kunnumakkara BB Aggarwal, Biochem Pharmacol 2008 75 787 809 10.1016/j.bcp.2007. 08.016 17900536
36. Cytotoxic effect of curcumin on malaria parasite Plasmodium falciparum: Inhibition of histone acetylation and generation of reactive oxygen species. L Cui J Miao L Cui, Antimicrob Agents Chemother 2007 51 488 494 10.1128/AAC.01238-06 17145789 (Pubitemid 46185265)
37. Curcumin for malaria therapy. RC Reddy PG Vatsala VG Keshamouni G Padmanaban PN Rangarajan, Biochem Biophys Res Comm 2005 326 472 474 10.1016/j.bbrc.2004.11.051 15582601 (Pubitemid 39593570)
38. Modulation of Plasmodium falciparum phagocytosis, inflammatory cytokines production and cytoadhesion molecules expression by the natural product curcumin. PN Mimche, PhD thesis EMBL/University of Milan-LSHTM, AntiMal programme 2010
39. Synthesis and exploration of novel curcumin analogues as anti-malarial agents. S Mishra K Karmodiya N Surolia A Surolia, Bioorg Med Chem 2008 16 2894 2902 10.1016/j.bmc.2007.12.054 18194869 (Pubitemid 351418213)
40. Facile oxidation of leucomethylene blue and dihydroflavins by artemisinins: Relationship with flavoenzyme function and antimalarial mechanism of action. RK Haynes WC Chan HN Wong KY Li WK Wu KM Fan HHY Sung ID Williams D Prosperi S Melato P Coghi D Monti, ChemMedChem 2010 5 1282 1299 10.1002/cmdc.201000225 20629071
41. Artemisinin directly targets malarial mitochondria through its specific mitochondrial activation. J Wang L Huang J Li Q Fan Y Long Y Li B Zhou, PLoS ONE 2010 5 9582 10.1371/journal.pone.0009582 20221395
42. Interactions of curcumin with the PfATP6 model and the implications for its antimalarial mechanism. HF Ji L Shen, Bioorg Med Chem Lett 2009 19 2453 2455 10.1016/j.bmcl.2009.03.060 19329310
43. Computational screening of molecular targets in Plasmodium for novel non resistant anti-malarial drugs. N Singh K Misra, Bioinformation 2009 3 255 262 19255645
44. Artemisinins target the SERCA of Plasmodium falciparum. U Eckstein-Ludwig RJ Webb IDA van Goethem JM East AG Lee M Kimura PM O'Neill PG Bray SA Ward S Krishna, Nature 2003 424 957 961 10.1038/nature01813 12931192 (Pubitemid 37051688)
45. Artemisinins: mechanisms of action and potential for resistance. S Krishna AC Uhlemann RK Haynes, Drug Resist Updat 2004 7 233 244 10.1016/j.drup.2004.07.001 15533761 (Pubitemid 39469096)
46. A single amino acid residue can determine the sensitivity of SERCAs to artemisinins. AC Uhlemann A Cameron U Eckstein-Ludwig J Fischbarg P Iserovich FA Zuniga M East A Lee L Brady RK Haynes S Krishna, Nat Struct Mol Biol 2005 12 628 629 10.1038/nsmb947 15937493 (Pubitemid 40980816)
47. Curcumin-artemisinin combination therapy for malaria. DN Nandakumar VA Nagaraj PG Vathsala P Rangarajan G Padmanaban, Antimicrob Agents Chemother 2006 50 1859 1860 10.1128/AAC.50.5.1859-1860.2006 16641461
48. Plasmodium chabaudi: Efficacy of artemisinin + curcumin combination treatment on a clone selected for artemisinin resistance in mice. A Martinelli LA Rodrigues P Cravo, Exp Parasitol 2008 119 304 307 10.1016/j.exppara.2008.02. 011 18397786
49. Platelets kill intraerythrocytic malarial parasites and mediate survival to infection. BJ McMorran VM Marshall C de Graaf KE Drysdale M Shabbar GK Smyth JE Corbin WS Alexander SJ Foote, Science 2009 323 797 800 10.1126/science. 1166296 19197068
50. Role of pro-oxidants and antioxidants in the anti-inflammatory and apoptotic effects of curcumin (diferuloylmethane). SK Sandur H Ichikawa MK Pandey AB Kunnumakkara B Sung G Sethi BB Aggarwal, Free Radic Biol Med 2007 43 568 580 10.1016/j.freeradbiomed.2007.05.009 17640567 (Pubitemid 47058232)
51. The relationship between the anti-inflammatory effects of curcumin and cellular glutathione content in myelomonocytic cells. EM Strasser B Wessner N Manhart E Roth, Biochem Pharmacol 2005 70 552 559 10.1016/j.bcp.2005.05.030 16002051 (Pubitemid 40978545)
52. High oxygen radical production is associated with fast parasite clearance in children with Plasmodium falciparum malaria. B Greve LAG Lehman B Lell D Luckner R Ott Schmidt PAG Kremsner, J Infect Dis 1999 179 1584 1586 10.1086/314780 10228089 (Pubitemid 29246617)
53. Vitamin E-deficient diets enriched with fish oil suppress lethal Plasmodium yoelii infections in athymic and scid/bg mice. D Taylor O Levander V Krishna C Evans V Morris J Barta, Infect Immun 1997 65 197 202 8975912 (Pubitemid 27008923)
54. Oxidative stress increases the expression of the CD36 scavenger receptor and the cellular uptake of oxidized low-density lipoprotein in macrophages from atherosclerotic mice: protective role of antioxidants and of paraoxonase. B Fuhrman N Volkova M Aviram, Atherosclerosis 2002 161 307 316 10.1016/S0021-9150(01)00646-3 11888513 (Pubitemid 34219183)
55. CD36 and malaria: friends or foes? L Serghides TG Smith SN Patel KC Kain, Trends Parasitol 2003 19 461 469 10.1016/j.pt.2003.08.006 14519584 (Pubitemid 38366143)
56. Spicing up of the immune system by curcumin. G Jagetia B Aggarwal, J Clin Immunol 2007 27 19 35 10.1007/s10875-006-9066-7 17211725
57. Immunomodulatory effects of curcumin: In-vivo. C Varalakshmi AM Ali BVV Pardhasaradhi RM Srivastava S Singh A Khar, Int Immunopharmacol 2008 8 688 700 10.1016/j.intimp.2008.01.008 18387511
58. Curcumin enhances non-inflammatory phagocytic activity of RAW264.7 cells. K Bisht WH Choi SY Park MK Chung WS Koh, Biochem Biophys Res Comm 2009 379 632 636 10.1016/j.bbrc.2008.12.135 19121625
59. Oxidised LDL up-regulate CD36 expression by the Nrf2 pathway in 3T3-L1 preadipocytes. M D'Archivio B Scazzocchio C Filesi R Var MT Maggiorella L Sernicola C Santangelo C Giovannini R Masella, FEBS Letters 2008 582 2291 2298 10.1016/j.febslet.2008.05.029 18514070
60. Role of protein kinase C [delta] in curcumin-induced antioxidant response element-mediated gene expression in human monocytes. SA Rushworth RM Ogborne CA Charalambos MA O'Connell, Biochem Biophys Res Comm 2006 341 1007 1016 10.1016/j.bbrc.2006.01.065 16460683 (Pubitemid 43221766)
61. The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-gamma. AM Siddiqui X Cui R Wu W Dong M Zhou M Hu HH Simms P Wang, Crit Care Med 2006 34 1874 1882 10.1097/01.CCM.0000221921.71300.BF 16715036 (Pubitemid 43982462)
62. Curcumin is not a ligand for peroxisome proliferator-activated receptor-gamma. VR Narala MR Smith RK Adapala R Ranga K Panati BB Moore T Leff VD Reddy AK Kondapi RC Reddy, Gene Ther Mol Biol 2009 13 20 25 19644570
63. Pathogenesis, clinical features, and neurological outcome of cerebral malaria. R Idro NE Jenkins CR Newton, Lancet Neurol 2005 4 827 840 10.1016/S1474-4422(05)70247-7 16297841 (Pubitemid 41619438)
64. Clinical significance of sequestration in adults with severe malaria. AM Dondorp, Transfus Clin Biol 2008 15 56 57 10.1016/j.tracli.2008.04.013 18501654
65. Cytokines: accelerators and brakes in the pathogenesis of cerebral malaria. NH Hunt GE Grau, Trends Immunol 2003 24 491 499 10.1016/S1471-4906(03) 00229-1 12967673 (Pubitemid 37088152)
66. Plasmodium falciparum-infected erythrocytes increase intercellular adhesion molecule 1 expression on brain endothelium through NF-kappaB. AK Tripathi DJ Sullivan MF Stins, Infect Immun 2006 74 6 3262 3270 10.1128/IAI.01625-05 16714553 (Pubitemid 43794513)
67. Plasmodium falciparum-infected erythrocytes induce NF-kappaB regulated inflammatory pathways in human cerebral endothelium. AK Tripathi W Sha V Shulaev MF Stins DJ Sullivan Jr, Blood 2009 114 4243 4252 10.1182/blood-2009-06-226415 19713460
68. The murine cerebral malaria phenomenon. NJ White GD Turner IM Medana AM Dondorp NP Day, Trends Parasitol 2009 26 11 15 10.1016/j.pt.2009.10.007 19932638
69. Neuropathogenesis of human and murine malaria. EM Riley KN Couper H Helmby JCR Hafalla JBd Souza J Langhorne W Jarra F Zavala, Trends Parasitol 2010 26 277 278 10.1016/j.pt.2010.03.002 20338809
70. Inhibition of tumor necrosis factor by curcumin, a phytochemical. MMY Chan, Biochemical Pharmacology 1995 49 1551 1556 10.1016/0006-2952(95)00171-U 7786295
71. Pharmacological basis for the role of curcumin in chronic diseases: An age-old spice with modern targets. BB Aggarwal B Sung, Trends Pharmacol Sci 2009 30 85 94 10.1016/j.tips.2008.11.002 19110321
72. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. DS Straus CK Glass, Trends Immunol 2007 28 551 558 10.1016/j.it.2007.09.003 17981503 (Pubitemid 350101420)
73. Disruption of Nrf2 enhances upregulation of nuclear factor-kappaB activity, proinflammatory cytokines, and intercellular adhesion molecule-1 in the brain after traumatic brain injury. W Jin H Wang W Yan L Xu X Wang X Zhao X Yang G Chen Y Ji, Mediators Inflamm 2008 2008 725174 10.1155/2008/725174 19190763
74. Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria. A Pamplona A Ferreira J Balla V Jeney G Balla S Epiphanio A Chora CD Rodrigues IP Gregoire M Cunha-Rodrigues S Portugal MP Soares MM Mota, Nat Med 2007 13 703 710 10.1038/nm1586 17496899 (Pubitemid 46889755)
75. The transcription factor Nrf2 is a therapeutic target against brain inflammation. NG Innamorato AI Rojo AJ Garcia-Yague M Yamamoto ML de Ceballos A Cuadrado, J Immunol 2008 181 680 689 18566435
76. Effect of curcumin on the adhesion of platelets to brain microvascular endothelial cells in vitro. L Zhang ZL Gu ZH Qin ZQ Liang, Acta Pharmacol Sin 2008 29 800 807 10.1111/j.1745-7254.2008.00813.x 18565277
77. Platelet-endothelial cell interactions in cerebral malaria: the end of a cordial understanding. D Faille F El-Assaad MC Alessi T Fusai V Combes GE Grau, Thromb Haemost 2009 102 1093 1102 19967139
78. Bacteraemia complicating severe malaria in children. J Berkley S Mwarumba K Bramham B Lowe K Marsh, Trans R Soc Trop Med Hyg 1999 93 283 286 10.1016/S0035-9203(99)90024-X 10492760 (Pubitemid 29348822)
79. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. RK Thimmulappa, J Clin Invest 2006 116 984 995 10.1172/JCI25790 16585964
80. The antimalarial artemisinin synergizes with antibiotics to protect against lethal live Escherichia coli challenge by decreasing proinflammatory cytokine release. J Wang H Zhou J Zheng J Cheng W Liu G Ding L Wang P Luo Y Lu H Cao S Yu B Li L Zhang, Antimicrob Agents Chemother 2006 50 2420 2427 10.1128/AAC.01066-05 16801421 (Pubitemid 43993181)
81. Treatment of severe sepsis with artemether-lumefantrine is associated with decreased mortality in ugandan patients without malaria. CC Moore ST Jacob R Pinkerton P Banura DB Meya SJ Reynolds N Kenya-Mugisha H Mayanja-Kizza WM Scheld Promoting Resource-Limited Interventions for Sepsis Management in Uganda (PRISM-U) Study Group, Am J Trop Med Hyg 2009 80 723 728 19407113
82. Curcumin therapeutic promises and bioavailability in colorectal cancer. A Shehzad S Khan O Shehzad YS Lee, Drugs Today (Barc) 2010 46 523 532 10.1358/dot.2010.46.7.1509560 20683505
83. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. G Shoba D Joy T Joseph M Majeed R Rajendran PS Srinivas, Planta Med 1998 64 353 356 10.1055/s-2006-957450 9619120 (Pubitemid 28234275)
84. Evaluation of an oral carrier system in rats: bioavailability and antioxidant properties of liposome-encapsulated curcumin. M Takahashi S Uechi K Takara Y Asikin K Wada, J Agric Food Chem 2009 57 9141 9146 10.1021/jf9013923 19757811
85. Novel formulation of solid lipid microparticles of curcumin for anti-angiogenic and anti-inflammatory activity for optimization of therapy of inflammatory bowel disease. VR Yadav S Suresh K Devi S Yadav, J Pharm Pharmacol 2009 61 311 321 10.1211/jpp.61.03.0005 19222903
86. Continued cytoadherence of Plasmodium falciparum infected red blood cells after antimalarial treatment. KR Hughes GA Biagini AG Craig, Mol Biochem Parasitol 2010 169 71 78 10.1016/j.molbiopara.2009.09.007 19800372
87. Nrf2 as a novel molecular target for chemoprevention. JS Lee YJ Surh, Cancer Letters 2005 224 171 184 10.1016/j.canlet.2004.09.042 15914268